Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATB1651 in Adults With Mild to Moderate Onychomycosis
NCT05089409Phase 1Completed
- Sponsor
- Amtix Bio
- Start
- Mar 2022
- Primary completion
- Jun 2023
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATB1651 in onychomycosis (6 arms), sponsored by Amtix Bio. Primary endpoint: Safety and Tolerability (Adverse Events) at 56 days. Started Mar 2022; status: completed.
02
Drugs
ATB1651
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT05089409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089409.